Literature DB >> 21160903

Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer.

Kebin Liu1.   

Abstract

The host immune system functions as a guardian against tumor development. It has been demonstrated that cytotoxic T lymphocyte (CTL)-mediated cytotoxic pathways function to inhibit or delay human colorectal cancer development. However, the host anti-tumor immune responses also 'edit' the tumor and select for more aggressive variants, resulting in immune evasion and tumor escape. Fas is a death receptor that mediates one of the major cytotoxic effector mechanisms of the CTLs. Fas is highly expressed in normal human colon epithelial cells but is frequently silenced in colorectal carcinoma, especially in metastatic colorectal carcinoma, suggesting that loss of Fas expression and function may be an immune evasion and tumor escape mechanism. In addition, recent studies indicated that Fas also mediates cellular proliferation signaling pathways to promote tumor development. Therefore, the death receptor Fas may not only transduce death signals to suppress tumor development but also activate cellular proliferation and the migration process to promote tumor growth and progression. Thus, understanding the mechanisms by which the Fas receptor and its associated protein complex transduces the death and survival signals may identify molecular targets for the development of therapeutic strategy to enhance the Fas-mediated death signals to increase the efficacy of cancer immunotherapy.

Entities:  

Keywords:  Apoptosis; Fas; Immune evasion; Metastasis

Year:  2010        PMID: 21160903      PMCID: PMC3000453          DOI: 10.4251/wjgo.v2.i11.399

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  85 in total

1.  Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations.

Authors:  Kebin Liu; Elwood McDuffie; Scott I Abrams
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

2.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  The CD95 receptor: apoptosis revisited.

Authors:  Marcus E Peter; Ralph C Budd; Julie Desbarats; Stephen M Hedrick; Anne-Odile Hueber; M Karen Newell; Laurie B Owen; Richard M Pope; Juerg Tschopp; Harald Wajant; David Wallach; Robert H Wiltrout; Martin Zörnig; David H Lynch
Journal:  Cell       Date:  2007-05-04       Impact factor: 41.582

4.  Fas ligand promotes tumor immune evasion of colon cancer in vivo.

Authors:  Aideen E Ryan; Fergus Shanahan; Joe O'Connell; Aileen M Houston
Journal:  Cell Cycle       Date:  2006-02-14       Impact factor: 4.534

5.  Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand.

Authors:  Ganwei Lu; Bratislav M Janjic; Jelena Janjic; Theresa L Whiteside; Walter J Storkus; Nikola L Vujanovic
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

Review 6.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

7.  TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.

Authors:  Christian H Poehlein; Hong-Ming Hu; Jane Yamada; Ilka Assmann; W Gregory Alvord; Walter J Urba; Bernard A Fox
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

8.  Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer.

Authors:  Mona Karlsson; Per Marits; Kjell Dahl; Tobias Dagöö; Sven Enerbäck; Magnus Thörn; Ola Winqvist
Journal:  Ann Surg Oncol       Date:  2010-01-30       Impact factor: 5.344

Review 9.  A multi-functional role of interferon regulatory factor-8 in solid tumor and myeloid cell biology.

Authors:  Scott I Abrams
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

10.  Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver.

Authors:  Hanchen Li; Xueli Fan; Calin Stoicov; Jian Hua Liu; Sharif Zubair; Elena Tsai; Ronald Ste Marie; Timothy C Wang; Stephen Lyle; Evelyn Kurt-Jones; Jeanmarie Houghton
Journal:  Gastroenterology       Date:  2009-06-12       Impact factor: 22.682

View more
  11 in total

1.  Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC.

Authors:  Yonghui Zhang; Hailin Zhang; Mei Wei; Tao Mou; Tao Shi; Yanyu Ma; Xinyu Cai; Yunzheng Li; Jie Dong; Jiwu Wei
Journal:  Mol Ther       Date:  2019-08-05       Impact factor: 11.454

2.  Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance.

Authors:  Mary A Zimmerman; Nur-Taz Rahman; Dafeng Yang; Guy Lahat; Alexander J Lazar; Raphael E Pollock; Dina Lev; Kebin Liu
Journal:  Cancer Res       Date:  2012-07-17       Impact factor: 12.701

3.  Kisspeptin effect on endothelial monocyte activating polypeptide II (EMAP-II)-associated lymphocyte cell death and metastases in colorectal cancer patients.

Authors:  Martha Stathaki; Athanasios Armakolas; Andreas Dimakakos; Loukas Kaklamanis; Ioannis Vlachos; Manoussos M Konstantoulakis; George Zografos; Michael Koutsilieris
Journal:  Mol Med       Date:  2014-03-18       Impact factor: 6.354

4.  Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer.

Authors:  Xiaolin Hu; Kankana Bardhan; Amy V Paschall; Dafeng Yang; Jennifer L Waller; Mary Anne Park; Asha Nayak-Kapoor; Thomas A Samuel; Scott I Abrams; Kebin Liu
Journal:  J Biol Chem       Date:  2013-05-15       Impact factor: 5.157

Review 5.  Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance.

Authors:  Konstantinos A Paschos; Ali W Majeed; Nigel C Bird
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

6.  CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis.

Authors:  Charalabos Pothoulakis; Monica Torre-Rojas; Marco A Duran-Padilla; Jonathan Gevorkian; Odysseas Zoras; Emmanuel Chrysos; George Chalkiadakis; Stavroula Baritaki
Journal:  Int J Cancer       Date:  2017-10-12       Impact factor: 7.316

7.  Peritoneal expression of Matrilysin helps identify early post-operative recurrence of colorectal cancer.

Authors:  Giuseppe S Sica; Cristina Fiorani; Carmine Stolfi; Giovanni Monteleone; Eleonora Candi; Ivano Amelio; Valeria Catani; Simone Sibio; Andrea Divizia; Giorgia Tema; Edoardo Iaculli; Achille L Gaspari
Journal:  Oncotarget       Date:  2015-05-30

8.  Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells.

Authors:  Renxiang Huang; Dongyang Zhang; Feng Li; Zili Xiao; Meiling Wu; Dongyun Shi; Ping Xiang; Zhijun Bao
Journal:  Oncol Lett       Date:  2017-03-22       Impact factor: 2.967

9.  Discussion of some 'knowns' and some 'unknowns' about the tumour suppressor p53.

Authors:  Elizabeth Lieschke; Zilu Wang; Gemma L Kelly; Andreas Strasser
Journal:  J Mol Cell Biol       Date:  2019-03-01       Impact factor: 6.216

10.  Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression.

Authors:  Amy V Paschall; Mary A Zimmerman; Christina M Torres; Dafeng Yang; May R Chen; Xia Li; Erhard Bieberich; Aiping Bai; Jacek Bielawski; Alicja Bielawska; Kebin Liu
Journal:  BMC Cancer       Date:  2014-01-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.